News
ACTU
3.000
+2.04%
0.060
Actuate Therapeutics management to meet with B. Riley
TipRanks · 2d ago
Weekly Report: what happened at ACTU last week (0420-0424)?
Weekly Report · 5d ago
Actuate Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 04/22 12:09
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
Benzinga · 04/22 11:59
Analysts Offer Insights on Healthcare Companies: Actuate Therapeutics, Inc. (ACTU), Iovance Biotherapeutics (IOVA) and Otsuka Holdings Co (OtherOTSKF)
TipRanks · 04/22 10:20
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/21 21:05
Health Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Reuters · 04/21 20:12
Weekly Report: what happened at ACTU last week (0413-0417)?
Weekly Report · 04/20 09:25
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 04/17 12:05
Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?
Benzinga · 04/16 07:34
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/15 21:05
ACTUATE THERAPEUTICS INC <ACTU.O>: B. RILEY CUTS TARGET PRICE TO $8 FROM $20
Reuters · 04/15 12:04
Actuate Publishes New Positive Phase 2 Data For Elraglusib In Pancreatic Cancer
NASDAQ · 04/15 10:02
U.S. RESEARCH ROUNDUP-Autodesk, Citigroup, Wells Fargo
Reuters · 04/15 08:34
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 04/14 21:05
Actuate Announces Publication In Nature Medicine Reporting Phase 2 Data Showing Elraglusib + Chemotherapy Improves Survival By >40% In Metastatic Pancreatic Cancer Trial
Benzinga · 04/14 12:47
Actuate says elraglusib plus chemo lifts median survival 40% in phase 2 pancreatic trial
PUBT · 04/14 12:46
ACTUATE THERAPEUTICS ANNOUNCES NATURE MEDICINE PUBLICATION OF CLINICAL TRIAL RESULTS SHOWING DOUBLING OF THE RATE OF SURVIVAL WITH ELRAGLUSIB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Reuters · 04/14 12:45
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 04/13 12:45
Actuate Therapeutics Price Target Cut to $15.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 04/13 11:07
More
Webull provides a variety of real-time ACTU stock news. You can receive the latest news about Actuate Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.